Have a feature idea you'd love to see implemented?
Let us know!
CRMD CorMedix Inc
Price (delayed)
$10.33
Market cap
$626.8M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.81
Enterprise value
$592.07M
CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company is focused on developing its
Highlights
The company's debt fell by 21% YoY and by 6% QoQ
The EPS has increased by 13% since the previous quarter and by 6% year-on-year
CorMedix's equity has decreased by 29% YoY but it has increased by 27% QoQ
CorMedix's net income has decreased by 16% YoY but it has increased by 13% from the previous quarter
The quick ratio has shrunk by 70% YoY and by 17% QoQ
The gross margin fell by 15% YoY
Key stats
What are the main financial stats of CRMD
Market
Valuations
Earnings
Shares outstanding
60.68M
Market cap
$626.8M
Enterprise value
$592.07M
Price to earnings (P/E)
N/A
Price to book (P/B)
9.83
Price to sales (P/S)
49.56
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
48.28
Revenue
$12.26M
EBIT
-$47.51M
EBITDA
-$47.32M
Free cash flow
-$56.15M
Per share
Balance sheet
Liquidity
EPS
-$0.81
Free cash flow per share
-$0.95
Book value per share
$1.05
Revenue per share
$0.21
TBVPS
$1.29
Total assets
$77.59M
Total liabilities
$18.87M
Debt
$556,416
Equity
$58.71M
Working capital
$54.67M
Debt to equity
0.01
Current ratio
3.96
Quick ratio
3.43
Net debt/EBITDA
0.73
Margins
Efficiency
Dividend
EBITDA margin
-385.9%
Gross margin
83.6%
Net margin
-376.3%
Operating margin
-415.6%
Return on assets
-64.7%
Return on equity
-79.2%
Return on invested capital
-214.3%
Return on capital employed
-80.4%
Return on sales
-387.5%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CRMD stock price
How has the CorMedix stock price performed over time
Intraday
-3.82%
1 week
-6.09%
1 month
-7.77%
1 year
185.36%
YTD
174.73%
QTD
27.85%
Financial performance
How have CorMedix's revenue and profit performed over time
Revenue
$12.26M
Gross profit
$10.25M
Operating income
-$50.96M
Net income
-$46.15M
Gross margin
83.6%
Net margin
-376.3%
The company's net margin has surged by 100% YoY and by 94% QoQ
CorMedix's operating margin has surged by 100% YoY and by 94% QoQ
The company's operating income fell by 22% YoY but it rose by 12% QoQ
CorMedix's net income has decreased by 16% YoY but it has increased by 13% from the previous quarter
Growth
What is CorMedix's growth rate over time
Valuation
What is CorMedix stock price valuation
P/E
N/A
P/B
9.83
P/S
49.56
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
48.28
The EPS has increased by 13% since the previous quarter and by 6% year-on-year
The P/B is 129% above the 5-year quarterly average of 4.3 and 97% above the last 4 quarters average of 5.0
CorMedix's equity has decreased by 29% YoY but it has increased by 27% QoQ
The price to sales (P/S) is 97% lower than the 5-year quarterly average of 1703.0
Efficiency
How efficient is CorMedix business performance
The return on sales has surged by 100% year-on-year and by 94% since the previous quarter
The company's return on invested capital fell by 41% YoY but it rose by 4.3% QoQ
CorMedix's ROE has decreased by 20% YoY but it has increased by 4% from the previous quarter
The ROA has contracted by 10% YoY but it has grown by 9% from the previous quarter
Dividends
What is CRMD's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CRMD.
Financial health
How did CorMedix financials performed over time
CorMedix's total liabilities has surged by 129% YoY and by 63% QoQ
The quick ratio has shrunk by 70% YoY and by 17% QoQ
The company's debt is 99% lower than its equity
CorMedix's equity has decreased by 29% YoY but it has increased by 27% QoQ
The company's debt fell by 21% YoY and by 6% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.